Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 7/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9931680 | 0.86 | PBRM1 (0.31) | PBRM1MALT1APP | |
| SCHEMBL9932366 | 0.86 | PBRM1 (0.31) | PBRM1MALT1APP | |
| SCHEMBL8532112 | 0.79 | CYP19A1 (0.40) | PBRM1CYP19A1MALT1APPMEN1 | |
| SCHEMBL8532115 | 0.79 | CYP19A1 (0.40) | PBRM1CYP19A1MALT1APPMEN1 | |
| SCHEMBL9882535 | 0.79 | CYP19A1 (0.40) | PBRM1CYP19A1MALT1APPMEN1 | |
| SCHEMBL9882483 | 0.75 | PBRM1 (0.40) | PBRM1CYP19A1MALT1APPMEN1 | |
| SCHEMBL8515666 | 0.75 | PBRM1 (0.40) | PBRM1CYP19A1MALT1APPMEN1 | |
| SCHEMBL9931351 | 0.74 | PBRM1 (0.38) | PBRM1CYP19A1MALT1MEN1KMT2A | |
| SCHEMBL12489864 | 0.72 | PBRM1 (0.38) | PBRM1CYP19A1MALT1MEN1KMT2A | |
| SCHEMBL12489867 | 0.72 | PBRM1 (0.38) | PBRM1CYP19A1MALT1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | GENENTECH, INC. | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | PBRM1 3853/4885CYP19A1 2497/4885MALT1 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.